About EvolutionaryScale
EvolutionaryScale is a company based in New York (United States) founded in 2023 by Thomas Hayes, Tom Sercu, Halil Akin, Roshan Rao, and Alexander Rives. EvolutionaryScale has raised $142 million across 1 funding round from investors including Amazon, Nat Friedman and Daniel Gross. EvolutionaryScale operates in a competitive market with competitors including Nimbus Therapeutics, Cradle, Evozyne, Profluent Bio and Frontier Medicines, among others.
- Headquarter New York, United States
- Founders Thomas Hayes, Tom Sercu, Halil Akin, Roshan Rao, Alexander Rives
- SectorsHealthcare
- Email••••••••
- Website evolutionaryscale.ai
- Social LinkedIn X
- Legal Name Sinapsis Ltd
- Total Equity Funding$142M (USD)
in 1 rounds
- Latest Funding Round$142M (USD), Seed
Jun 2024
- InvestorsAmazon
& 4 more
Funding Insights of EvolutionaryScale
EvolutionaryScale has successfully raised a total of $142M through 1 strategic funding round. The most recent funding activity was a Seed round of $142 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $142M
- Total Rounds 1
- Last Round Seed — $142M
- First Round $142M
(Jun 2024)
- Investors Count 5
All 1 funding rounds of EvolutionaryScale with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2024 | $142M | Seed | – | Nat Friedman, Daniel Gross |
5 investors in total: 3 institutional and 2 angel.
Investors in EvolutionaryScale
EvolutionaryScale has secured backing from 5 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include Amazon, Nat Friedman and Daniel Gross.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and early-stage technology companies are funded by Lux Capital. | – | luxcapital.com | Menlo Park, United States | |
Venture capital arm of Nvidia | – | nventures.ai | Santa Clara, United States | |
Multi-category products are offered through an online marketplace. | 1994 | amazon.com | Seattle, United States | |
NF Nat Friedman | Former GitHub CEO, AI investor, active angel in tech startups | – | unknown_5305b8001be94f81a | - |
DG Daniel Gross | Co-founder of Cue, AI pioneer, active angel investor in tech startups. | – | unknown_0df69d892fdf4843a | - |
Investor details for EvolutionaryScale
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EvolutionaryScale
5 people are tracked at EvolutionaryScale (5 in leadership).
| Name | Role | Group |
|---|---|---|
Thomas Hayes | Co-Founder | Leadership |
Tom Sercu | Co-Founder | Leadership |
Halil Akin | Co-Founder | Leadership |
Roshan Rao | Co-Founder | Leadership |
Alexander Rives | Co-Founder & CEO | Leadership |
Complete people profiles for EvolutionaryScale
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of EvolutionaryScale
2 dated milestones of EvolutionaryScale across 1 years, from founding to its latest funding, stage changes and deals.
- Founded EvolutionaryScale is founded.
- Funding First funding round of $142.0M.
Competitors of EvolutionaryScale
EvolutionaryScale operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Cradle, Evozyne, Profluent Bio and Frontier Medicines, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| cradle.bio | 2021 | Delft, Netherlands | $102.71M | – | Chemoproteomics solutions are provided for protein design and development. | |
| evozyne.com | 2020 | Chicago, United States | $144.37M | – | Developer of proteins using protein engineering technology | |
| profluent.bio | 2022 | Berkeley, United States | $44M | – | An AI-based protein design platform is provided for drug discovery. | |
| frontiermeds.com | 2018 | San Francisco, United States | $235.5M | 115 | Bioinformatics platform is developed for drug discovery and chemoproteomics. | |
| eikontx.com | 2019 | Hayward, United States | $1.16B | – | Protein dynamics are tracked and measured for drug discovery processes. | |
| entactbio.com | 2022 | Watertown, United States | $120.9M | – | Drugs are developed to enhance functions of beneficial proteins. |
Detailed competitors of EvolutionaryScale
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of EvolutionaryScale
The website of EvolutionaryScale (evolutionaryscale.ai) receives about 13.4K visits a month.
- Monthly visits13.4K
▼ 27.8% vs previous month
Websites whose visitors overlap most with EvolutionaryScale. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biorxiv.org | 100% | 3M | #19,954 | View details | |
| nature.com | 80% | 33.6M | #1,922 | View details | |
| arxiv.org | 68% | 24.2M | #2,532 | View details | |
| overleaf.com | 61% | 36.7M | #1,656 | View details | |
science.org | science.org | 57% | – | #9,517 | – |
Latest news on Evolutionaryscale
Complete news archive for EvolutionaryScale
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to EvolutionaryScale
10 companies that operate in the same segment as EvolutionaryScale (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about EvolutionaryScale
EvolutionaryScale was founded in 2023 and raised its 1st funding round 1 year after it was founded.
EvolutionaryScale is headquartered in New York, United States. It is registered at New York, New York, United States.
Alexander Rives is the current CEO of EvolutionaryScale. They have also founded this company.
EvolutionaryScale is a funded company, having raised a total of $142M across 1 funding round to date. The company's 1st funding round was a Seed of $142M, raised on Jun 2024.
EvolutionaryScale was founded in 2023 and is headquartered in New York, United States. Operations focus on the biotechnology sector, where AI-driven models for protein engineering are provided. The companys ESM3 model is utilized to analyze protein sequences, structures, and functions simultaneously. Services support research in biological applications, with a team of co-founders leading development efforts.
EvolutionaryScale's top competitors include Nimbus Therapeutics, Cradle and Profluent Bio.
EvolutionaryScale has 5 investors. Key investors include Amazon, Nat Friedman, Daniel Gross, Lux Capital, and NVentures.
EvolutionaryScale operates through Sinapsis Ltd.